Vaccine Platform and Technology
ViraVac offers innovative solutions to treating and preventing the most pressing infectious diseases around the world.
Antigen design and vaccine construction
Our proprietary vaccines are based on modified avian orthoavulavirus 1 (AOaV-1), which is isolated from birds and are harmless in humans.
We optimise genetic instructions (genes) to make highly stable immunogenic protein of a pathogen and insert it into the AOaV-1 vector.
The AOaV-1 vaccine vectors are formulated into a vaccine. Upon delivery to host, it undergoes several rounds of self-limiting replication and delivers genetic instructions into a host to elicit robust immune responses against the target pathogen.
AOaV-1 expresses the antigens in self-limiting replication manner
- When the vaccine interacts with the body cell, AOaV-1 binds to the receptors located on the surface of cells.
- Inside the cell, the genetic instructions are arranged into correct order for translation.
- Using cells’ own machinery, the vector produces several thousand copies of the antigens.
- The newly formed antigens undergo structural modifications to generate peptides, which are used to elicit immune responses involving B cells and T cells.
Action of antigenic peptides-specific T and B cells
B and T cells are key players in mounting effective immune responses against pathogens.
- Specific antigenic peptides are associated with MHC class I molecules leads to activation of CD8+ cytotoxic T cells.
- Specific antigenic peptides are associated with MHC class II molecules leading to activation of CD4+ cytotoxic T cells.
- Naïve B cells are activated to produce antibodies.
Actions of B cells and Activated T cells in the control of disease
- When B cell encounter pathogen, plasma cells start producing antibodies to neutralise pathogen.
- Also, the activated T cells selectively identify the pathogen infected diseases cells and eliminate them by lysis (killing).
The compounding affect of B and T cells reduces pathogen load to the host and thus disease severity is reduced.
In the unfortunate event of an outbreak, only the digital genetic information of the pathogen is needed to generate ViraVac recombinant vaccine. Using the genetic information and our innovative pipelines, the genes are optimised and stabilised on computer. Within the next 3 weeks, the genetic information is cloned into ViraVac’s proprietary vector and the recombinant vaccine is rescued in well established substrates. To ensure the stability and robustness in replication, the vaccine is expanded under several immunological pressures for the next 2–3 weeks. These vaccine formulations are amplified and are ready for the safety, tolerability, and immunogenicity in vivo and for GMP manufacturing.